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Abstract
Background: Most health economic evaluations of childhood vaccination only capture the health and short-term
economic benefits. Measuring broader, long-term effects of vaccination on productivity and externalities could
provide a more complete picture of the value of vaccines.
Method: MEDLINE, EconLit and NHS-EED databases were searched for articles published between January 1990 and
July 2011, which captured broader economic benefits of vaccines in low and middle income countries. Studies
were included if they captured at least one of the following categories on broader economic impact:
outcome-related productivity gains, behaviour-related productivity gains, ecological externalities, equity gains,
financial sustainability gains or macroeconomic benefits.
Results: Twenty-six relevant studies were found, including observational studies, economic models and contingent
valuation studies. Of the identified broader impacts, outcome-related productivity gains and ecological externalities
were most commonly accounted for. No studies captured behaviour-related productivity gains or macroeconomic
effects. There was some evidence to show that vaccinated children 8–14 years of age benefit from increased
cognitive ability. Productivity loss due to morbidity and mortality was generally measured using the human capital
approach. When included, herd immunity effects were functions of coverage rates or based on reduction in disease
outcomes. External effects of vaccines were observed in terms of equitable health outcomes and contribution
towards synergistic and financially sustainable healthcare programs.
Conclusion: Despite substantial variation in the methods of measurement and outcomes used, the inclusion of
broader economic impact was found to improve the attractiveness of vaccination. Further research is needed on
how different tools and techniques can be used in combination to capture the broader impact of vaccination in a
way that is consistent with other health economic evaluations. In addition, more country level evidence is needed
from low and middle income countries to justify future investments in vaccines and immunization programs.
Finally, the proposed broader economic impact framework may contribute towards better communication of the
economic arguments surrounding vaccine uptake, leading to investments in immunization by stakeholders outside
of the traditional health care sector such as ministries of finance and national treasuries.
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Background
In the last two decades, several vaccines have been
developed that target a range of infectious diseases of
global public health importance [1]. However, the list
price of these vaccines in high income countries is sub-
stantially greater than for traditional vaccines [2]. Hence
governments and external funders with limited resources
often have to trade off purchasing vaccines against
investing in other preventative and therapeutic interven-
tions. In many high income countries, assessment of the
relative cost-effectiveness of competing strategies is a key
element to the adoption of new health technologies [3],
alongside other considerations such as effectiveness,
disease burden and equity impact. Such analyses usually
focus on the health sector impact of vaccination, weighing
the cost of an immunization program against the morbid-
ity and mortality prevented, as well as potential savings
derived from a reduction in health care utilization.
However, it has been suggested that these cost effect-
iveness analyses may present too narrow a perspective of
the benefits of vaccination [4,5] and other child health
programs [6]. This is particularly relevant to many low
and middle income countries (LMICs), where decisions
about health care spending are often made in the con-
text of wider development goals, and not on issues
restricted to the health care sector alone [7]. Further-
more, many such countries do not have locally estab-
lished decision rules to facilitate the optimal allocation
of resources within a fixed health care budget [8], so wider
considerations such as the impact of immunization on
economic growth or national budgets are often highly
relevant.
Aside from their effectiveness in reducing disease and
mortality, the economic benefits of vaccination have
usually been measured in terms of the averted costs of
medical care. Sometimes consideration is also made of
the immediate productivity loss to patients (as a result
of illness or death) and their carers. However, in the
longer term, it has been suggested that vaccines can in-
crease lifetime productivity due to better physical health,
decreased chance of cognitive impairment caused by
some vaccine preventable diseases, and better educa-
tional outcomes through increased school attendance
[4,9]. It has also been suggested that reduced childhood
mortality may encourage mothers to decrease the num-
ber of planned births, hence increasing household in-
vestment per child and enabling greater labor force
participation [4,10]. In the long run, decreasing fertility
may improve the dependency ratio and increase invest-
ment in physical and human capital [11,12].
On a community level, vaccination is associated with
positive externalities due to its effect on the pathogen-
host ecology [2,13]. For instance, vaccination can de-
crease the infection risk of unvaccinated people since
they will no longer be at risk of becoming infected by
vaccinated people (herd immunity). The use of vaccines
may also reduce the need for antimicrobial use against
affected organisms, hence reducing antimicrobial resist-
ance. Vaccination programs may also improve the finan-
cial sustainability and affordability of healthcare
programs in LMICs. Their use as part of a treatment
cluster, or in combination with other infrastructure pro-
jects (such as water management systems) to maximize
community health outcomes, offers opportunities for
cost sharing between programs. Additionally, introduc-
tion of vaccination to disease endemic areas may boost
private demand for vaccines within communities, which
could enable partial cost recovery by health departments
[14-22].
Traditional health economic evaluations only consider
the sector-specific impact of interventions on the health
care sector. However, large outbreaks of diseases such as
cholera or pandemic influenza can affect other sectors of
the economy such as manufacturing, tourism and trans-
port [2,9,23,24]. In countries with a high disease burden,
vaccination may modulate such outbreaks, and have a
substantial impact on demand, supply, trade and invest-
ment in the wider economy.
Recently, several frameworks have been proposed by
which these wider benefits of vaccination can be cate-
gorised [4,9]. However, the extent to which these
broader benefits are considered in current economic
evaluations of vaccines is unclear. This systematic review
aims to identify the extent to which broader economic
benefits are already incorporated within existing eco-
nomic evaluations of vaccines in LMICs, and to examine
the validity of the underlying methodologies and asso-
ciated outcomes employed in estimating their effect.
Through the use of a narrative approach, we investigate
how inclusion of these broader effects could impact on
the performance of healthcare programs, and also ex-
plore the potential for incorporating them within
metrics which can be adequately interpreted by decision
makers looking to compare returns on investment (ROI)
against those in other sectors.
Methods
A systematic review was conducted to identify economic
evaluations capturing the benefits of vaccination apart
from (i) health effects (morbidity and mortality averted),
(ii) health treatment costs saved and (iii) short term
productivity losses due to being ill or caring for someone
ill. For the purpose of this review, “narrow benefits” are
defined as health effects, healthcare costs and short-
term productivity losses to patients and caregivers.
These benefits are typically incorporated into traditional
economic evaluations. They are generally short-term
(lasting not much longer than the duration of the illness
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and its sequelae) and are restricted to the vaccinated in-
dividual and closely related individuals (such as care-
givers). “Broader” benefits are defined as potential
benefits of vaccination aside from these; they typically
involve longer term effects and/or wider externalities
other than individuals vaccinated and their caregivers.
The framework proposed in Bärnighausen et al. [4]
also differentiates between narrow and broad benefits on
these grounds. However, following our review we
expanded Bärnighausen’s framework to encompass other
externalities and macroeconomic-level benefits proposed
in recent literature [9]. In our classification, benefit cat-
egories were grouped under three broad headings de-
pending on whether they related to health gains
(narrow), productivity gains or community externalities
(see Table 1). Productivity gains related to outcomes
were divided into narrow short-term outcomes (immedi-
ate disease or death) and long-term outcomes (effects of
better health leading to improved physical, educational
and cognitive outcomes).
We reviewed MEDLINE, EconLit and the National
Health Service Economic Evaluation Database (NHS-
EED) for English language articles published between
January 1990 and July 2011. Search filters for identifying
papers specific to vaccination, economic outcomes and
LMICs were then applied in combination. In addition,
specific keywords associated with the various benefit cat-
egories were also included in the search in combination
with these filters. A separate search was conducted for
the broader benefits identified by Bärnighausen et al. [4]
(category B3-4 and C1-4 in Table 1), using category spe-
cific keywords. Full search terms can be found in the
additional file [see Additional file 1]. Grey literature
reports and working papers published online were also
identified through discussions with subject experts
involved in a World Health Organization consultation on
the broader economic impact of vaccination (Toronto,
2011). To ensure reproducibility of search results, grey lit-
erature reports not publicly available on the internet were
excluded. Reference lists in identified articles were
scanned to identify additional studies missed during the
search (snowball method).
Each study identified through the database search was
initially categorized on the basis of its title and abstract
to determine its possible relevance to the review. Studies
could be economic evaluations, reviews, epidemiological
studies (observational or experimental), contingent valu-
ation studies or descriptions of measurement tools.
Table 1 Categorized list of the benefits of vaccination
Category Definition Examples of outcomes
A. Health-related benefits
A1. Health gains Reduction in morbidity and mortality Cases averted
Deaths averted
Disability-adjusted life years saved
A2. Health care savings Reduction in cost of health care borne
by the public sector or private individuals
Costs saved
B. Productivity-related benefits
B1. Productivity gains related to care Reduction in lost days of work due to
sickness or caring for a sick patient
Value of productivity gained
B2. Productivity gains related to
short term outcomes
Reduction in lost days of work due to
sickness or death of sick patient
Value of productivity gained
Lifetime earnings
B3. Productivity gains related to long
term outcomes
Increased lifetime productivity because better
health improves cognition, educational
attainment and physical strength
Educational outcomes
Cognitive outcomes
Lifetime earnings
B4. Productivity gains related to
household behaviour
Economic improvements due to changes in
household choices such as fertility and
consumption/saving as a result of improved
child health and survival
Productivity
Female labour participation
Household investment per child
Dependency ratio
C. Community externalities
C1. Ecological effects Health improvements in unvaccinated community
members as a result of ecological effects such as
herd immunity and reduced antibiotic usage.
Indirect vaccine protection
Prevalence of antibiotic resistance
C2. Equity More equal distribution of health outcomes Distribution of health outcomes
C3. Financial sustainability Improved financial sustainability of health care
programs as a result of synergies with vaccination
programs and/or stimulation of private demand.
Financial benefits
Private demand estimates
C4. Macroeconomic impact Changes in the national economy or
individual sectors of the economy.
Gross domestic product
Production by economic sector
Definitions in categories A, B and C1 are adapted from Bärnighausen et al. [4].
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Articles were then read to ensure that they met the fol-
lowing criteria: (i) in humans, (ii) not studies of travel
vaccines, (iii) discussed or measured at least one of the
benefits of vaccination listed in categories B3-4 or C1-4
of Table 1, (iv) conducted in LMICs, (v) discussed both
cost and benefits of vaccines, (vi) discussed economic
consequences of vaccine use (and not purely epidemio-
logical studies looking at the impact of vaccination on
infection or disease).
Results
Overview
Full texts of 92 articles were obtained. Of these, 26 were
found to meet the selection criteria, and were included
in the qualitative synthesis. Three of these 26 studies
were grey literature reports or working papers and were
not retrieved from a database [25-27]. A PRISMA flow
diagram of search results [see Additional file 2], and a
detailed description of all included studies [see Additional
file 3] can be found as additional files. Half the studies
incorporated both narrow and broad economic benefits of
vaccination, while the other half solely incorporated
broader benefits. Perhaps reflective of growing interest in
the measurement of broader benefits, only three included
studies were published in 2005 or earlier [11,14,28]. Five
studies also estimated economic gains from vaccine use in
multiple LMICs [11,22,29-31].
Table 2 shows the number of articles mentioning dif-
ferent categories of benefit, and the associated vaccine
antigens and targeted age groups discussed. While there
were no clear patterns, on the whole outcome-related
productivity gains and equity were discussed most often
in articles dealing with vaccines targeted at children
under five years old. Financial sustainability was dis-
cussed most often in articles dealing with vaccines tar-
geted at both children and adults. Ecological externalities
were discussed equally often in both types of articles.
Also, the majority of the studies using a willingness-to-
pay approach to estimate societal value of a vaccine were
in articles dealing with older age groups (Table 1).
Productivity gains related to long-term outcomes (B3)
Productivity gains related to long-term outcomes were
included in eight studies [11,22,25-27,30-32]. Three were
primary studies (one cluster randomised trial [25] and two
observational longitudinal studies [26,32]) examining the
long term productivity effects of vaccination against child-
hood diseases. Barham and Calimeris [25] used a quasi-
randomised cluster design to find that early childhood
vaccination combined with a family planning program in
Bangladesh significantly improved cognitive outcomes in
later childhood. The effect was equivalent to completing
three years of primary school. Bloom et al. [32] found that
children in the Philippines who received a package of six
vaccines by age two years had significantly better scores
on cognitive tests at 10–11 years old. However, Kumar
[26] found mixed evidence in India. Children receiving
vaccines in the universal immunization program had
lower primary school completion rates, but higher second-
ary school completion rates. Kumar suggested that the
disappointing primary school completion results could be
due to poorer health among the children who would not
have survived without vaccination, or lower household in-
vestment in children due to their unexpected survival.
Five studies explored techniques for converting gains
in cognitive ability into measurable economic benefits
that can be used in economic evaluations. Connolly and
Constenla [27] examined the effect that vaccination may
have on net tax revenues, via productivity gains as a re-
sult of changes to health and educational outcomes.
Hence reduced disease could result in improved educa-
tion, and a subsequent increase in tax revenue later in
life. Bloom et al. [11] used the link between health and
wages [10] to project the long-term economic benefit of
improved childhood health. Tebbens et al. [30] projected
the lifetime impact of averting paralysis due to polio in a
cost-effectiveness analysis of the global polio eradication
initiative. Stack et al. [31] estimated the economic im-
pact of vaccines in 72 countries eligible for assistance
through the GAVI Alliance. This incorporated both nar-
row benefits (health care costs) as well as productivity
loss due to both long-term disability and premature
Table 2 Number of articles by vaccine antigen, target age
range and category of broader benefit mentioned
Outcome-
related
productivity
Financial
sustainability
Ecological
externalities
Equity
Children only (under five years)
Diptheria, tetanus,
pertussis
1
Haemophilus
influenzae type B
3 1
Hepatitis A 3 1
Hepatitis B
Malaria 1
Measles 3 2
Meningitis 5
Pertusiss 1
Pneumococcus 2 1 3
Polio 3 1 1
Rotavirus 4
Tuberculosis 3 1
Yellow fever 2
Children and adults
Cholera 4 4
Dengue 1
Malaria 2
HIV 1 1
Typhoid 1
Total* 32 12 8 5
* Totals add up to more than 26 because some articles discuss multiple
vaccine antigens.
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mortality. An extension of this study also estimated the
value of deaths averted using the value of statistical life
approach, which measures willingness to pay to avert
such deaths [22].
Ecological externalities (C1)
Vaccination can reduce disease incidence in unvaccin-
ated individuals by preventing infection transmission
from vaccinated to unvaccinated individuals. This posi-
tive externality is called indirect or “herd” protection.
The size of the externality is a nonlinear function of the
proportion of the population vaccinated [33]. Ecological
externalities were captured in five cost-effectiveness ana-
lyses [34-38] and three cost-benefit analyses [20,39,40].
One of the cost-benefit analyses was based on
willingness-to-pay values from a contingent valuation
study [20]. Of these, six captured the effect of ecological
externalities in the base case [20,34,35,37,39,40] and two
in sensitivity analyses [36,38]. All the studies found that
including herd immunity resulted in more favorable
cost-effectiveness or cost-benefit ratios and an increase
in the predicted number of cases averted by vaccination.
Giglio et al. [37] opted for the simplest (and most ap-
proximate) approach, assuming that the number of indir-
ectly prevented cases is just a multiple of the number of
directly vaccinated individuals. Kim et al. [36] and Vespa
et al. [38] examined the cost-effectiveness of different
pneumococcal conjugate vaccines in the Gambia and Bra-
zil respectively. They accounted for herd protection (as
well as serotype replacement) by constructing various sce-
narios about the magnitude of this effect based on the
post-vaccination experience of other countries such as the
United States. However, the most complete approach was
to incorporate herd protection using epidemiological
models that represent infection transmission between
infected and susceptible individuals. Jeuland et al.
[35,39,40] and Cook et al. [20] conducted cost-
effectiveness and cost-benefit evaluations of cholera vac-
cines in several LMICs. Herd protection was assumed to
be a function of vaccine coverage using results from epi-
demiological models by Longini et al. [41]. They found
that herd protection effects were a key factor in the differ-
ent economic attractiveness of school-based versus
community-based vaccination programes. Lopez et al.
[34] developed a de novo transmission dynamic model
which could capture the indirect benefit of vaccination to
examine the cost-effectiveness of hepatitis A vaccination
in Argentina.
Equity (C2)
Cost-effectiveness analysis usually considers an improve-
ment in health to be of equal value regardless of the per-
son whose health is improved. However, public
investment in vaccination may change the distribution
of health in a population. Two studies have suggested
that the greatest gains may be in sections of the popula-
tion who are disadvantaged in terms of their existing
health or their socioeconomic status, thus reducing
health inequalities [28,42]. A study of measles vaccin-
ation in Bangladesh found that unvaccinated children in
the poorest quintile were more than twice as likely to
die as those from the least poor quintile, and that vac-
cination reduced socioeconomic status- related mortality
differentials [28]. Similarly, a study of delivering a pack-
age of five vaccines in Ghana found that children from
poorer households benefit more from immunization
than those from relatively better-off households [42].
Sustainability (C3)
Immunization programs provide opportunities for cost-
sharing and external funding with other health and social
interventions, through their ability to be included as part
of combined treatment packages, development projects or
social initiatives like poverty reduction campaigns. Three
evaluations estimated the cost-effectiveness of vaccination
when used alongside another public health intervention
[29,30,40]. Jeuland and Whittington [40] found a greater
percentage of their model scenarios to have a favorable
cost-benefit ratio for combination strategies of vaccination
and water supply improvements versus just vaccination.
Additionally, the cost-benefit ratio varied depending on
the order sequence of water pump installation and vaccin-
ation initiation. Similarly, Niessen et al. [29] investigated
the cost-effectiveness of multiple interventions (including
vaccination) against pneumonia, and found that different
combinations of expanding vaccine coverage with com-
munity or facility-based case management, nutritional
programs, or indoor air pollution measures maximized
child health by providing the greatest health yield per dol-
lar spent. Such studies are especially useful for conditions
such as pneumonia in which non-bacterial causes can be
major contributors towards disease burden.
Vaccination programs may also improve health care
infrastructure and supply chains that could also be used
for other public health initiatives. Tebbens et al. [30]
found that polio eradication programs had previously
unaccounted for net benefits associated with vitamin A
supplement delivery.
Immunization programs can result in increased de-
mand for vaccines. When the cost of vaccine purchase is
subsidized, some members of the population may be
able and willing to pay out-of-pocket to be vaccinated,
which would reduce the financial burden on the health-
care system. Nine of the reviewed studies estimated pri-
vate demand for vaccination using a willingness-to-pay
approach [14-22]. These suggested that unvaccinated
individuals could be protected at no extra cost if the
government set a user fee that was below the average
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willingness-to-pay for a particular vaccine. In certain
situations, it may even be possible to set user charges at
levels sufficient for partial cost recovery without loss of
demand. Interestingly, several of the studies also incor-
porated the social benefit of herd immunity in their
assessments [20,39].
Hence, generation of private demand could improve the
affordability and financial sustainability of immunization
programs. However, issues such as ensuring that vaccines
are available to members of the population unable to pay
user charges and avoiding free riders who rely on indirect
protection only will need to be considered.
Discussion
This review shows that several broader categories of
economic benefits associated with vaccination in LMICs
are being captured in primary studies and quantified in
economic evaluations. Our search identified 26 studies
which assessed at least one broader benefit of an
immunization program.
The first category involves productivity gains because
of reduced disease risk. Of these, productivity gains
related to care and to short-term outcomes are more
commonly captured in economic evaluations. Productiv-
ity gains related to long-term outcomes and to house-
hold behavior are not commonly estimated or
incorporated in economic evaluations [4]. There may be
a number of reasons for this. Firstly, evidence for many
of the proposed benefits of vaccination is still limited.
Vaccine trials do not routinely incorporate cognitive,
educational and behavioral outcomes. Furthermore, the
final endpoint in such an analysis is the productivity of
an adult of working age who either was or was not vacci-
nated as a child. Such an endpoint may occur too long
after the vaccination event to be feasibly collected. There
are also ethical problems in keeping trial participants
unvaccinated once a vaccine has been shown to be safe
and effective. Hence existing evidence is largely based
around retrospective observational cohorts, which may
be biased since they rely on controls with unvaccinated
individuals.
Secondly, the economic modeling framework within
which such benefits can be incorporated is still unclear.
While many of the reviewed studies were able to quan-
tify the productivity-related benefits of vaccination, apart
from care-related and short-term outcome-related prod-
uctivity effects this was not routinely incorporated into
summary statistics such as cost-effectiveness or cost-
benefit ratios. The most common means of incorporat-
ing productivity gains was the human capital approach,
which values the remaining years of productive employ-
ment a person can have up to retirement based on na-
tional average incomes [43]. However, this method only
captures productivity loss due to death or disability, and
not due to cognitive or educational deficits as a result of
childhood illness. Furthermore, the method has been cri-
ticized in its own right, since it assumes that the work a
sick or deceased worker does cannot be replaced by
someone currently unemployed or by simply reassigning
it to other workers [44]. Possibly for this reason, lost in-
come as a result of premature death was rarely incorpo-
rated in the reviewed studies, even when economic
evaluations used the human capital approach to value
productivity loss. Other methods (such as the friction
cost approach) are less likely to overestimate productiv-
ity loss due to illness, but are equally difficult to use to
capture the effects of long-term outcomes [44].
None of the studies accounted for behavior related
productivity gains such as potential reductions in fertility
as a result of improved child survival. In principle, life-
time benefit models (such as by Connolly and Constenla
[27] and Bloom et al. [11]) are able to quantify the effect
of demographic changes such as dependency ratio
improvements or productivity changes from increased
female workforce participation. However, primary stud-
ies are still needed to explore the link between vaccin-
ation and household decisions such as childbearing and
investment spending.
Value of statistical life methodology, used by Ozawa
et al. [22], offers a different approach by valuing lives
based on individuals’ willingness to pay to reduce the
risk of death rather than the economic output accrued
to a year of life. This method often produces estimates
of monetary value of prevented deaths that are far
greater than those estimated using other methods (see
for example Molinari et al. [45]). While this does not
mean it is wrong, it does raise issues of comparability
with existing economic evaluations and burden estimates
conducted using more conservative methods. Another
challenge in applying this methodology on a global level
is the difficulty in knowing the extent to which to apply
normative values on life (which mostly originate from
high income countries) across national borders. Trad-
itional cost-effectiveness analyses sidestep this problem
by valuing health equally across the world in non-
monetary terms; differences in decision making across
countries hence stem from differences in thresholds
representing societal willingness to pay for health (which
reflect differences in budgets and national priorities) and
in the direct economic impact of disease.
Ecological externalities, particularly herd immunity,
were the most common broader benefit to be incorpo-
rated into economic evaluations. This is likely to be be-
cause the techniques for such analyses (such as the use
of “transmission dynamic models”) are already well-
established in the epidemiological and health economics
fields [13]. However, many LMICs lack the capacity and/
or surveillance systems to perform and parameterize
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these sophisticated analyses [46]. For example, infection
transmission models capturing the indirect effects of
vaccination may require data on behavioral and contact
patterns which are not readily available in many LMICs.
Besides herd immunity, negative ecological externalities
may also occur such as replacement of strains of patho-
gens eliminated by vaccination with other strains un-
affected by vaccination [13].
Equity, affordability and financial sustainability are
often important considerations for vaccine introduction
in LMICs. However, trials do not to routinely collect
economic information by socioeconomic strata. Such
data would enable analyses of the impact of vaccines on
equity or financial sustainability of other interventions,
as well as elucidate any methodological difficulties with
incorporating them into standard cost-effectiveness
frameworks. This is evident in the case of certain spill
over effects of immunization programs. Reuse of
immunization infrastructure, better surveillance, human
resource gains, and improved drug procurement systems,
are some potential benefits of immunization programs
which are rarely incorporated into cost effectiveness stud-
ies [47]. Other frameworks such as return on investment
analyses or optimization modeling may be able to address
some of these issues more effectively, and provide more
comprehensive representation of the societal value of
vaccination.
None of the identified studies took a macroeconomic
approach to evaluating the impact of vaccination, as
proposed by a recent World Health Organization guid-
ance document [9]. Such an approach has been used to
evaluate the impact of vaccination during an influenza
pandemic in several European countries, using comput-
able general equilibrium models [48], but an LMIC appli-
cation or an application to situations beyond pandemics
(such as an endemic disease) has yet to be published.
This review has limitations, because it was designed to
give a broad qualitative overview of existing literature ra-
ther than to enable detailed quantitative synthesis. Only
one person was responsible for study selection, and the
studies were not weighted by quality scores. However,
the permissive inclusion criteria ensured that a variety of
study types and measurement techniques were reviewed,
including those employing unconventional tools and
techniques. Also, our study was restricted to methods
applied to LMICs only, since it was motivated by deci-
sion making in these settings, where stakeholders often
require information not provided by conventional eco-
nomic evaluation methods. As a result, it may not have
captured novel approaches being developed or applied
in high income settings.
Most (22/26) of the reviewed studies included only a
single category of broader economic impact. There may
be several reasons for this. Most (16/26) studies were
observational, willingness to pay, return on investment
or cost of illness studies rather than full economic eva-
luations (cost-effectiveness or cost-benefit analyses)
attempting to capture all important costs and outcomes
of an intervention. However, even the full economic eva-
luations presented a limited number of broader categor-
ies of impact, even though a comprehensive range of
traditional (narrow) measures were presented, such as
direct medical costs, cases avoided or lives saved. This
may be due to the current novelty of these measures, as
well as the lack of comprehensive guidelines for eco-
nomic evaluations about which of these broader mea-
sures should be reported and in what way. A further
difficulty is the complexity of the relationships between
vaccination, health and broader economic outcomes,
which require a range of types of evidence and techni-
ques to quantify. Given the difficulty with both measure-
ment and interpretation, it may be impractical to
develop a single composite measure capturing all rele-
vant economic benefits of vaccination. Instead, several
evaluation techniques may need to be implemented to
obtain a representative set of outcome measures. How-
ever, there is little guidance about the way several cat-
egories of benefits estimated using different techniques
can be combined in the same evaluation.
Conclusions
Broader categories of economic benefits such as those
reviewed here offer valuable information to decision
makers, especially those outside the health sector. However,
further work on techniques to value such categories and
combine them in economic evaluations is still needed.
Key recommendations arising from this review are sum-
marized below:
 Studies linking changes in health to long-term
behavioral and developmental outcomes are needed,
as well as techniques to analyze observational
studies in ways that reduce potential biases.
 Information needs of stakeholders from different
sectors (including health, finance and external
donors) should be obtained to guide incorporation
of broader benefits into economic evaluation, as well
as their effective communication.
 Guidelines from decision makers and agencies
setting standards for economic evaluations are
needed about appropriate ways to incorporate
broader economic benefits, particularly about
combining several benefit categories or evaluation
techniques.
 Pilot testing and validations studies of evaluations
based on such normative guidelines should be
conducted in LMICs.
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